Source: Annual Congress 2009 - Drug effects in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. O. Tandogdu, E. Eryuksel, S. Karakurt, H. Senol, T. Celikel (Istanbul, Turkey). Influence of statin therapy on exacerbation frequency in patients with COPD. Eur Respir J 2009; 34: Suppl. 53, 2009

Member's Comments

No comment yet.

Related content which might interest you: Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019 Year: 2019 Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Effect of asthma and asthma medication on the prognosis of patients with COVID-19 Source: Eur Respir J, 57 (3) 2002226; 10.1183/13993003.02226-2020 Year: 2021 Effect of roflumilast in patients with severe COPD and a history of hospitalisation Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017 Year: 2017 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Duration of systemic corticosteroids treatment in COPD exacerbations Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Variability in exacerbation frequency in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 264s Year: 2002 Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD Source: ERJ Open Res, 4 (3) 00087-2018; 10.1183/23120541.00087-2018 Year: 2018 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses Source: International Congress 2017 – COPD management Year: 2017